Big Changes to Drug Prior Authorization? CMS Proposal Explained

Why It Matters

Electronic prior authorization will streamline drug access, cutting delays and administrative costs for providers and patients, while establishing a data‑driven standard for future health‑care reforms.

Key Takeaways

• CMS proposes electronic prior auth for all prescription drugs by 2027
• Applies to Medicare Advantage, Medicaid, CHIP, and ACA plans
• Requires same API for medical benefit drugs as non‑drug services
• Sets deadlines for plan decisions and annual performance reporting
• Aims to cut forms, reduce burden for patients, clinicians

Summary

The Centers for Medicare & Medicaid Services (CMS) has issued a proposed rule to overhaul prior authorization (PA) for prescription drugs, mandating electronic submissions across all Medicare Advantage, Medicaid, CHIP, and ACA plans starting October 2027. The rule builds on recent efforts to digitize PA for non‑drug services and leverages existing API standards.

Key provisions include using the same API for medical‑benefit drugs as for non‑drug items, applying Medicare Part D electronic PA standards to retail prescriptions, and imposing strict timelines for insurers to render PA decisions. Plans must also report annual PA performance metrics, creating a transparent accountability framework.

CMS officials highlighted that the proposal aligns with congressional initiatives to simplify PA, reduce paperwork, and alleviate administrative strain on clinicians and patients. The agency cites existing infrastructure as proof that the transition is both pragmatic and technically feasible.

If adopted, the rule could dramatically shorten approval cycles, lower operational costs for providers, and improve medication access, potentially setting a new national benchmark for digital health workflows.

Original Description

Michael Anne Kyle from The University of Pennsylvania breaks down CMS's proposed rule that aims to improve prior authorization for prescription drugs by requiring electronic prior authorization, setting deadlines, and promoting transparency through annual reporting.

Read the full article: https://www.healthaffairs.org/content/forefront/understanding-cms-s-proposed-rule-regarding-prior-authorization-drugs?utm_medium=youtube&utm_source=forefront&utm_campaign=kyle

Sign up for our free newsletter to catch up on all the latest health policy news and analysis: https://www.healthaffairs.org/newsletters

---

Visit Health Affairs: http://www.healthaffairs.org

Subscribe and Listen to our Podcasts: https://www.healthaffairs.org/podcasts

Sign up for our free Newsletters: https://www.healthaffairs.org/newsletters